Abstract
Abstract: :
Purpose: To determine the effect of Acular® (ketoralac tromethamine) ophthalmic solution 0.5% on myopic regression in patients who were overcorrected following LASIK treatment for myopia. Methods: Refractive outcome data from 23 eyes of 18 patients who experienced overcorrection after LASIK treatment for myopia was analyzed retrospectively. Refractive surgery on 23 myopic eyes was performed at one center using the NIDEK EC 5000 Excimer Laser. Manifest spherical equivalent (MSE), uncorrected Snellen visual acuity (UCVA), and best-corrected Snellen Visual acuity (BCVA) were obtained pre-operatively at 1 week, 1 month, and 3 months. Residual hyperopia observed post-operatively was treated with topical Acular® 3-4 times per day. Results: The LASIK procedure in all 23 eyes was uneventful with no intra-operative complications. Twenty-three eyes were followed at 1 week, 16 eyes were followed at 1 month, and 12 eyes completed 3-month follow-up. Acular® treatment was initiated in 22 of 23 eyes within 7 days post-operatively. The mean MSE pre-operatively was -6.09 diopters (D) and ranged from -10.25 D to -2.13 D. At 1 week post-operatively, MSE was +1.48 D and ranged from +3.50 D to +0.75 D. Mean UCVA achieved at 1 week was 20/40 and mean BCVA was 20/25. At 1 month, MSE was +1.06 D with a range from +2.50 D to -0.13 D. Mean UCVA achieved was 20/30 and mean BCVA was 20/20 at 1 month. At 3 months, MSE decreased to +0.75 D with a range from +0.25 D to -1.25 D. Mean UCVA achieved at 3 months was 20/30 and mean BCVA was 20/20. Conclusion: Treatment with Acular® 0.5% initiated within 1 week of LASIK appears to promote myopic regression in overcorrected patients when the hyperopia exceeds +1.25 D. No treatment benefit was observed from use of Acular® in lower levels of post-operative hyperopia secondary to overcorrection.
Keywords: 548 refractive surgery: LASIK • 545 refractive surgery: complications • 544 refractive surgery